Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Avantor (NYSE: AVTR) delivers essential materials and technologies powering breakthroughs in life sciences and advanced industries. This news hub provides investors and professionals with direct access to official announcements, including product innovations, financial results, and strategic partnerships shaping the future of bioprocessing and semiconductor manufacturing.
Track critical updates across Avantor's core operations: earnings disclosures detailing performance in pharmaceutical solutions, regulatory filings impacting global supply chains, and advancements in sustainable production methods like their viral vector processing systems. Discover how developments in brands like J.T. Baker and Macron Fine Chemicals influence research and manufacturing efficiency worldwide.
Our curated news collection serves as a decision-making tool for monitoring Avantor's role in enabling scientific progress across 180+ countries. Bookmark this page for real-time insights into leadership changes, facility expansions, and emerging applications in gene therapy support systems.
Avantor (AVTR) announced that CEO Michael Stubblefield will step down from his position as Director, President and Chief Executive Officer upon the appointment of a successor. The Board has initiated a search process with an executive search firm to identify the next CEO.
Board Chairman Jonathan Peacock acknowledged Stubblefield's decade of leadership, during which he transformed Avantor into a global player in the life sciences tools space. Stubblefield will be retained by the Board until February 2026 to provide ad hoc input for the leadership transition.
The company aims to identify a successor with a proven track record in delivering growth and value creation. Avantor highlighted its position as a durable platform with differentiated capabilities, broad portfolio, and global customer base and supply chain.
Avantor (NYSE: AVTR) reported Q1 2025 financial results with net sales of $1.58 billion, showing a 6% decrease (2% organic decline) from Q1 2024. The company posted net income of $64.5 million and Adjusted EBITDA of $269.5 million.
Key financial metrics include diluted GAAP EPS of $0.09, adjusted EPS of $0.23, operating cash flow of $109.3 million, and free cash flow of $82.1 million. The Laboratory Solutions segment saw an 8% decrease in net sales to $1.07 billion, while Bioscience Production segment reported a 1% decrease to $516.4 million.
In response to ongoing funding and policy-related headwinds, Avantor announced an expanded cost transformation initiative targeting $400 million in gross run-rate savings by the end of 2027. The company's adjusted net leverage stood at 3.2x as of March 31, 2025.
Avantor Inc announces its participation at INTERPHEX, showcasing advanced fluid handling technologies for bioprocessing applications. The company will demonstrate solutions including Magnetic Mixing Systems, MasterSense™ smart ecosystem for Masterflex® peristaltic pumps, and J.T.Baker® Direct Dispense Systems for buffer management.
Key highlights include their scalable Magnetic Mixing Systems, ranging from 10L tabletop to 1500L systems, designed for single-use closed systems with minimal shear impact on biologics. The MasterSense pump system features smart digital capabilities, offering precision fluid transfer with real-time monitoring and customizable protocol programming.
The showcase emphasizes Avantor's focus on scalability, flexibility, and efficiency in biologics production, supporting various applications from media preparation to final formulation.
Avantor (NYSE: AVTR), a leading global provider of mission-critical products and services to life sciences and advanced technology industries, has scheduled its first quarter 2025 earnings release for Friday, April 25, 2025, before market opening.
The company will host a conference call to discuss the results at 8:00 a.m. Eastern Daylight Time on the same day. Investors can access a live audio webcast through the Events & Presentations section of Avantor's investor relations website at ir.avantorsciences.com. A replay will be available for 30 days following the presentation.
Avantor (NYSE: AVTR) has completed a major expansion at its flagship European manufacturing facility in Gliwice, Poland, significantly enhancing its hydration solutions production capabilities. The new facility quadruples the site's capacity for manufacturing, formulating, and filling USP purified water and WFI-based hydration solutions, important components in buffer preparations and cell culture media.
The expansion is part of Avantor's strategic investments in global production capacity, following recent developments at their Aurora, Ohio site and a doubled output of synthesized salts at the Phillipsburg, N.J. facility. In November 2024, the company also opened a new 60,000-square-foot Bridgewater Innovation Center in New Jersey, doubling its lab and pilot plant capacity for bioprocessing innovation.
Avantor (NYSE: AVTR), a leading provider of mission-critical products and services for life sciences and advanced technology industries, has announced its participation in an upcoming investor event. President and CEO Michael Stubblefield will present at TD Cowen's 45th Annual Health Care Conference on March 5, 2025, at 11:50 a.m. EST.
Interested parties can access a live audio webcast of the presentation through the Events & Presentations section in the Investor area of Avantor's website at ir.avantorsciences.com. The presentation recording will remain available for replay on the website for 30 days following the event.
Silq Technologies and NuSil Technology , an Avantor (NYSE: AVTR) subsidiary, have formed a collaboration agreement to implement Silq's zwitterionic surface treatment technology on medical devices made with NuSil silicone products. The technology has shown potential to reduce medical implant-associated infections and complications without antibiotics, while also mitigating fibrosis, thrombosis, and enhancing surface lubricity.
Silq, a UCLA spin-off company, has developed a scalable method for applying permanent zwitterion surface treatment to implantable devices. Their ClearTract® Foley catheter, already FDA-cleared and being commercialized in the US, has shown promising results in preliminary clinical trials, with final results pending publication.
The partnership aims to expand the technology's application to various implantable medical devices that currently face complications leading to infections and premature device failure.
Avantor (AVTR) reported Q4 2024 results with net sales of $1.69 billion, showing a 2% decrease but 1% organic growth. Q4 net income reached $500.4 million with adjusted EBITDA of $307.7 million. Diluted GAAP EPS was $0.73 and adjusted EPS $0.27.
For full year 2024, net sales were $6.78 billion, declining 3% with a 2% organic decrease. Annual net income was $711.5 million with adjusted EBITDA of $1,198.8 million. The company achieved operating cash flow of $840.8 million and free cash flow of $768.3 million.
By segment, Laboratory Solutions reported Q4 sales of $1.13 billion, down 5%, while Bioscience Production showed Q4 sales of $560.8 million, up 4%. The company's bioprocessing platform grew high-single-digits, with management expressing confidence in achieving near-term and long-term financial goals.
TriLink BioTechnologies, a Maravai LifeSciences company (NASDAQ: MRVI), has announced a strategic partnership with Avantor, Inc. (NYSE: AVTR) to expand its nucleic acid products distribution across Europe, Middle East, and Africa (EMEA). The collaboration aims to streamline ordering processes and reduce lead times for European customers.
The partnership will increase accessibility to TriLink's product portfolio, including CleanCap® cap analogs, catalog mRNAs, modified and unmodified nucleotides, and CleanScribe® RNA Polymerase. These products will be available for research use only (RUO) or at GMP-grade through VWR's eCommerce platform, MarketSource.
TriLink, with over 25 years of experience in nucleic acid development, offers CDMO services and specializes in mRNA capping analogs, including CleanCap® M6, mRNA raw materials, and advanced scale-up capabilities.
Avantor (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, has announced it will release its fourth quarter and full year 2024 financial results before market opens on Friday, February 7, 2025.
The company will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Standard Time. A live audio webcast will be available in the Events & Presentations section of Avantor's investor website, with a replay accessible for 30 days.
